Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2021

View Archived Issues

ConserV and Lawrence Livermore National Laboratory collaborate on broad-spectrum coronavirus vaccine

Dosing begins in phase I/II study of TP-0184 as treatment of anemia in patients with MDS

GC-019-F autologous CAR T-cell therapy receives IND approval in China

First patient dosed in second phase II study of AD-109 in obstructive sleep apnea

FDA clears IND application for TERN-501 to be developed as treatment for NASH

European Commission approves Enhertu for HER2-positive breast cancer

Ivermectin found useful in patients with nonsevere COVID-19 disease

Bayer synthesizes new P2X3 receptor antagonists

New IL-17 modulators discovered at UCB

ZM-32, a novel muscone derivative that inhibits breast tumor angiogenesis in vivo

Shanghai Pharmaceuticals Holding patents Wee1-like protein kinase inhibitors

IMPACT Therapeutics identifies ATR kinase inhibitors

Organ-on-a-chip bests standard toxicity tests

Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present factor XIa inhibitors

FDA accepts IND application for PBCAR19B for NHL

Targeting the cartilage EGFR pathway is a promising therapeutic strategy in OA

GPR68-PKC pathway protects the brain from acidosis-induced neuronal injury

Gemcitabine can be repurposed as anti-HEV agent, in particular for HEV-infected cancer patients

New SIRP-alpha antibodies inducing tumor cell phagocytosis without affecting T-cell functionality

Caladrius opens phase IIb trial of CLBS-16 for coronary microvascular dysfunction

Lixte and City of Hope enter agreement to study LB-100 in phase Ib study for extensive stage SCLC

Clinical hold for planned phase I/II trial of HST-003 for knee cartilage regeneration

LMR-101 ameliorates symptoms of epilepsy in rodents

Aclaris reports topline phase IIa data on ATI-450 for rheumatoid arthritis

FDA approves Verquvo for heart failure

Aptorum cleared to begin phase I study in Canada with ALS-4 for S. aureus infections